The health care industry's latest corporate takeover features the world's largest biotechnology company, Amgen, agreeing to acquire Onyx Pharmaceuticals and its portfolio of cancer-fighting drugs for $10.4 billion.
The transaction is among the largest in the pharmaceutical sector this year and a shot in the arm for a broader M&A market whose global deal value fell through the year's first half.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
